UCB gets FDA nod for NayzilamNayzilam is the first and only FDA-approved nasal option for treating seizure clusters. Upsher-Smith launches education resources for migraine patientsUpsher-Smith's redesigned website for Qudexy XR includes information about migraine disease and patient savings. AbbVie gets FDA nod for Skyrizi AbbVie's Skyrizi provides a treatment for moderate-to-severe plaque psoriasis in adults. US Bioservices to exclusively dispense Diacomit US Bioservices will dispense Diacomit, which comes in capsules and powder for oral suspension. Adma Biologics gets FDA nod for Asceniv Adma Biologics expects to launch its intravenous immune globulin during the second half of 2019. TherapeuticsMD to offer Bijuva Bijuva is the only FDA-approved therapy combining bio-identical estradiol and progesterone in a single capsule to treat moderate to severe vasomotor symptoms due to menopause. Cipla, Pulmatrix reach agreement to develop Pulmazole The agreement enables Cipla’s entry into the branded specialty respiratory space. Janssen's Balversa gets FDA nod Janssen's Balversa is the first personalized treatment targeting susceptible genetic alternations for patients with metastatic bladder cancer. FDA approves Plenity from Gelesis Plenity is a new non-stimulant, non-systemic aid in weight management based on proprietary hydrogel technology. ViiV Healthcare's Dovato gets FDA nod Dovato is a two drug complete regimen for HIV-infected patients, who have never received antiretroviral treatment. First Previous 38 39 40 41 42 Next Last
